NAT10: An RNA cytidine transferase regulates fatty acid metabolism in cancer cells.
NAT10
ac4C
cancer
fatty acid metabolism
Journal
Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
14
08
2022
received:
11
05
2022
accepted:
23
08
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
N-4 cytidine acetylation (ac4C) is an epitranscriptomics modification catalyzed by N-acetyltransferase 10 (NAT10); important for cellular mRNA stability, rRNA biogenesis, cell proliferation and epithelial to mesenchymal transition (EMT). However, whether other crucial pathways are regulated by NAT10-dependent ac4C modification in cancer cells remains unclear. Therefore, in this study, we explored the impact of NAT10 depletion in cancer cells using unbiased RNA-seq. High-throughput sequencing of knockdown NAT10 in cancer cells was conducted to identify enriched pathways. Acetylated RNA immunoprecipitation-seq (acRIP-seq) and RIP-PCR were used to map and determine ac4C levels of RNA. Exogenous palmitate uptake assay was conducted to assess NAT10 knockdown cancer cells using Oil Red O staining and lipid content analysis. Gas-chromatography-tandem mass spectroscopy (GC/MS) was used to perform untargeted lipidomics. High-throughput sequencing of NAT10 knockdown in cancer cells revealed fatty acid (FA) metabolism as the top enriched pathway through the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis in differentially downregulated genes. FA metabolic genes such as ELOLV6, ACSL1, ACSL3, ACSL4, ACADSB and ACAT1 were shown to be stabilised via NAT10-dependent ac4C RNA acetylation. Additionally, NAT10 depletion was shown to significantly reduce the levels of overall lipid content, triglycerides and total cholesterol. Further, NAT10 depletion in palmitate-loaded cancer cells showed decrease in ac4C levels across the RNA transcripts of FA metabolic genes. In untargeted lipidomics, 496 out of 2 279 lipids were statistically significant in NAT10 depleted cancer cells, of which pathways associated with FA metabolism are the most enriched. Conclusively, our results provide novel insights into the impact of NAT10-mediated ac4C modification as a crucial regulatory factor during FA metabolism and showed the benefit of targeting NAT10 for cancer treatment.
Sections du résumé
BACKGROUND
N-4 cytidine acetylation (ac4C) is an epitranscriptomics modification catalyzed by N-acetyltransferase 10 (NAT10); important for cellular mRNA stability, rRNA biogenesis, cell proliferation and epithelial to mesenchymal transition (EMT). However, whether other crucial pathways are regulated by NAT10-dependent ac4C modification in cancer cells remains unclear. Therefore, in this study, we explored the impact of NAT10 depletion in cancer cells using unbiased RNA-seq.
METHODS
High-throughput sequencing of knockdown NAT10 in cancer cells was conducted to identify enriched pathways. Acetylated RNA immunoprecipitation-seq (acRIP-seq) and RIP-PCR were used to map and determine ac4C levels of RNA. Exogenous palmitate uptake assay was conducted to assess NAT10 knockdown cancer cells using Oil Red O staining and lipid content analysis. Gas-chromatography-tandem mass spectroscopy (GC/MS) was used to perform untargeted lipidomics.
RESULTS
High-throughput sequencing of NAT10 knockdown in cancer cells revealed fatty acid (FA) metabolism as the top enriched pathway through the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis in differentially downregulated genes. FA metabolic genes such as ELOLV6, ACSL1, ACSL3, ACSL4, ACADSB and ACAT1 were shown to be stabilised via NAT10-dependent ac4C RNA acetylation. Additionally, NAT10 depletion was shown to significantly reduce the levels of overall lipid content, triglycerides and total cholesterol. Further, NAT10 depletion in palmitate-loaded cancer cells showed decrease in ac4C levels across the RNA transcripts of FA metabolic genes. In untargeted lipidomics, 496 out of 2 279 lipids were statistically significant in NAT10 depleted cancer cells, of which pathways associated with FA metabolism are the most enriched.
CONCLUSIONS
Conclusively, our results provide novel insights into the impact of NAT10-mediated ac4C modification as a crucial regulatory factor during FA metabolism and showed the benefit of targeting NAT10 for cancer treatment.
Identifiants
pubmed: 36149760
doi: 10.1002/ctm2.1045
pmc: PMC9505754
doi:
Substances chimiques
Fatty Acids
0
Palmitates
0
Triglycerides
0
Cytidine
5CSZ8459RP
RNA
63231-63-0
Cholesterol
97C5T2UQ7J
Transferases
EC 2.-
Acetyltransferases
EC 2.3.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1045Informations de copyright
© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Références
Mol Cell. 2022 Aug 4;82(15):2797-2814.e11
pubmed: 35679869
EBioMedicine. 2019 May;43:238-252
pubmed: 31047858
J Am Chem Soc. 2018 Oct 10;140(40):12667-12670
pubmed: 30252461
Signal Transduct Target Ther. 2021 May 3;6(1):173
pubmed: 33941767
Cancers (Basel). 2019 Dec 13;11(12):
pubmed: 31847105
J Biol Chem. 2014 Sep 19;289(38):26201-26212
pubmed: 25086048
Clin Sci (Lond). 2019 Aug 7;133(15):1745-1758
pubmed: 31358595
Diabetes Metab Syndr Obes. 2020 Sep 25;13:3337-3348
pubmed: 33061495
Cell. 2018 Dec 13;175(7):1872-1886.e24
pubmed: 30449621
Curr Oncol Rep. 2022 May;24(5):659-670
pubmed: 35230593
Nat Med. 2016 Apr;22(4):427-32
pubmed: 26950360
J Transl Med. 2015 May 07;13:146
pubmed: 25947066
Biochem Biophys Res Commun. 2014 Feb 7;444(2):270-5
pubmed: 24462768
Clin Transl Med. 2022 May;12(5):e738
pubmed: 35522942
Nature. 2020 Jul;583(7817):638-643
pubmed: 32555463
J Cell Biochem. 2021 Dec;122(12):1936-1945
pubmed: 34605570
Nat Chem Biol. 2018 Nov;14(11):1010-1020
pubmed: 30150682
Oncogene. 2021 Jan;40(1):97-111
pubmed: 33082557
Acta Pharm Sin B. 2022 Aug;12(8):3313-3325
pubmed: 35967285
Carcinogenesis. 2017 Apr 1;38(4):402-410
pubmed: 28334272
Biochem Biophys Res Commun. 2017 Mar 11;484(3):565-571
pubmed: 28132807
J Mol Cell Biol. 2021 Sep 11;13(6):433-444
pubmed: 33755174
Curr Drug Targets. 2020;21(14):1397-1404
pubmed: 31721710
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2016 Sep 06;6:32922
pubmed: 27596041
Apoptosis. 2017 Jun;22(6):865-876
pubmed: 28386750
Cell Physiol Biochem. 2019;52(3):397-407
pubmed: 30845379
Histol Histopathol. 2017 Jul;32(7):687-698
pubmed: 27714708
Adv Exp Med Biol. 2021;1280:231-241
pubmed: 33791986
ACS Chem Biol. 2017 Dec 15;12(12):2922-2926
pubmed: 29039931
J Biol Chem. 2014 Dec 26;289(52):35724-30
pubmed: 25411247
Clin Transl Med. 2022 Sep;12(9):e1045
pubmed: 36149760
Sci Rep. 2019 Jul 31;9(1):11112
pubmed: 31366994
Int J Mol Sci. 2022 Feb 16;23(4):
pubmed: 35216285
J Gastrointest Oncol. 2020 Aug;11(4):695-707
pubmed: 32953153
Oncogenesis. 2017 Feb 27;6(2):e299
pubmed: 28240737
Int J Cancer. 2020 Dec 1;147(11):3019-3028
pubmed: 32441315
Br J Cancer. 2020 Jan;122(1):4-22
pubmed: 31819192
Nat Cancer. 2021 Apr;2(4):414-428
pubmed: 34179825
Stem Cells Int. 2021 Apr 12;2021:8833527
pubmed: 33953754
Crit Rev Oncol Hematol. 2016 Jan;97:15-21
pubmed: 26558689
Metabolomics. 2021 Sep 3;17(9):80
pubmed: 34480220
Mol Ther Nucleic Acids. 2021 Jul 02;26:135-147
pubmed: 34513300
NAR Cancer. 2021 Sep 09;3(3):zcab035
pubmed: 34514415
Eur J Pharmacol. 2021 Oct 15;909:174397
pubmed: 34332918
Br J Cancer. 2020 Jan;122(2):258-265
pubmed: 31819193
Anal Chem. 2016 Dec 6;88(23):11946-11954
pubmed: 27783898
Cancers (Basel). 2021 Mar 06;13(5):
pubmed: 33800852
Nutrients. 2018 Dec 01;10(12):
pubmed: 30513730
Oncol Lett. 2018 Aug;16(2):1390-1396
pubmed: 30008815